Bristol-Myers Squibb/Pfizer Alliance Announces anIndependent Medical Education Grant RFP

Advancing Management and Care in Atrial
Fibrillation and Venous Thromboembolism
I. BackgroundPfizer and Bristol-Myers Squibb (BMS) are collaborating to provide grant support for continuing professional
education in the areas of atrial fibrillation and venous thromboembolism. We are committed to supporting
innovative, independent medical education for healthcare professionals.
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g.,research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need thatare aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) thatprovides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal
Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing
the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible
for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer and BMS
must not be involved in any aspect of project development, nor the conduct of the independent education program.

3Advancing Management and Care in Atrial Fibrillation and Venous Thromboembolism

II. Eligibility
Geographic Scope:

GlobalApplicant Eligibility
Criteria•

The following may apply: medical, dental, nursing, allied health, and/orpharmacy professional schools; healthcare institutions (both large andsmall); professional associations and medical societies; medicaleducation companies; and other entities with a mission related tohealthcare professional education and/or healthcare improvement.

•If the project involves multiple departments within an institution and/or
between different institutions / organizations / associations. all institutions
must have a relevant role and the requesting organization must have a
key role in the project.

•For projects offering continuing education credit, the requestingorganization must be accredited.

Date RFP Issued•

June 28, 2022

Clinical Area•

Atrial Fibrillation/Venous Thromboembolism

III. Requirements

General Area of Interestfor this RFP:

Projects that will be considered for support will focus on improving the care ofpatients by addressing knowledge gaps in following areas. Grant proposals
can address either Direct Oral Anticoagulant (DOAC) management in Atrial
Fibrillation (AF) or Venous Thromboembolism (VTE) or both areas.
AF and stroke prevention:•Advance knowledge of clinical, economic, and social burden•

Review latest clinical and real-world evidence data, guideline
recommendations for optimized care, and practice challenges•

The importance of individualized and subpopulations including but notlimited to: Elderly/Frail, multiple comorbidities including renal, obesity,
GI bleeding risk, CV interventions, etc.

•AF detection and diagnosis:
oThe impact and importance of increasing diagnosis efforts onpatient outcomesoAF screening evidence and recommendations including
emerging technological systemic strategies to increase
appropriate diagnosis in at risk populations

oPatient focus: increase understanding of consumer driven AF

1

3Advancing Management and Care in Atrial Fibrillation and Venous Thromboembolism

screening, HCP and patient roles, shared decision making,challenges, opportunities, and how best to navigate barriers ofsocial determinants of healthcare disparities•AF burden:oIncrease awareness of knowledge gaps for various definitions
and measures of AF burdenoReview current evidence for threshold of AF burden thatwarrants anticoagulation for stroke preventiono

AF burden and future monitoring techniques

Venous Thromboembolism (VTE):•

Latest evidence (including RWE), guideline recommendations, as wellas emerging research and future of practice•VTE diagnosis, treatment, length of treatment in prevention ofrecurrent VTE, and transition of care between secondary and primary
careo

Individualized care (VTE bleeding and thrombosis risk
assessment based on patient characteristic(s)oRole of DOACs in Cancer associated VTE

Best Practices:•

What can we learn from other therapeutic areas/ practices to optimize
outcomes in NVAF and VTE?

The intent of this RFP is to support independent education initiatives forhealthcare professionals. Patient education programs are also in scope forthis RFP.
Various formats and designs will be considered, with priority given to thosethat leverage innovative data and content delivery mechanisms including anomnichannel approach (an integrated approach between multiple channels ofeducation and engagement).
A successful proposal should include:• Clear and concise statement of the goal, learning objectives, andexpected outcomes of the educational initiative• Learning plan that incorporates innovative techniques designed toengage learners, promotes application of education into practice, andincorporates a patient-centered approach to care2

3Advancing Management and Care in Atrial Fibrillation and Venous Thromboembolism••

Tools that provide HCP learners the opportunity to facilitate change toimprove patient outcomes
Measurement of outcomes, inclusive of learner progression
throughout the activity, extent to which the activity closed theidentified practice gaps, and patient impact

It is not our intent to support traditional interventional clinical research
projects. Projects evaluating the efficacy of therapeutic or diagnostic agentswill not be considered.

Target Audience:•Cardiologists, Interventional Cardiologists, Oncologists, Primary Care
Providers, Emergency Department (ED) physicians, VTE specialists,
Hematologists, Pulmonologists, Allied Healthcare Professionals (ie,NPs, PAs, pharmacists), and other healthcare professionals involved inthe care of patients with CV disease; as well as patients and caregivers

Expected Approximate
Monetary Range ofGrant Applications:•The grant maximum under this RFP will be up to $250,000 USD for
initiatives with large potential reach and impact. Requests forregional/multi-country educational proposals are within scope. Singlecountry programs will not be considered. We anticipate supporting
approximately 4 grants.

Key Dates:•RFP release date: June 28, 2022•

Grant Application due date: August 3, 2022•

Anticipated Grant Award Notification Date: September 2022•

Grants will be distributed following a fully executed agreement.

•Anticipated Start Date: November 2022**Start date will be individualized and dependent on decision notification
date. Processing time may take longer for organizations outside of the U.S.

How to Submit:•Please go to www.cybergrants.com/pfizer/knowledge and sign in. Firsttime users should click “Create your password”. [Note: there are individualportals for each grant application type (e.g., knowledge, LOI, research fullproposal, and QI full proposal). Please be sure to use the URL above.]•Click the “Start A New Knowledge Gap Application” button.

•In the application:o

For the question “What type of request are you submitting?”
select Response to a Request for Proposal (RFP)o

For the question “Are you replying to a Request for Proposal(RFP) as part of the Competitive Grant Program?” select YesoSelect the following Competitive Grant Program Name: 2022
IM G: Advancing Management and Care in AFIB and VTEo

Select the following Primary Area of Interest: CVM - Anti3

3Advancing Management and Care in Atrial Fibrillation and Venous Thromboembolism

coagulation (AFIB, VTE)
•Requirements for submission: Complete all required sections of theonline application and upload your project proposal (see Appendix) inthe General RFP Submission field.

•

If you encounter any technical difficulties with the website, please click
the “Technical Questions” link at the bottom of the page.

IMPORTANT: Be advised applications submitted after the due date will not
be reviewed by the committee.

Questions:•If you have questions regarding this RFP, please direct them in writing
to the Grant Officer, Jessica Romano (Jessica.Romano@pfizer.com),with the subject line “RFP Advancing Management and Care in Atrial
Fibrillation and Venous Thromboembolism.”

Grant Agreements:•If your grant is approved, your institution will be required to enter into a
written grant agreement with Pfizer. Please click here to view the coreterms of the agreement.
Pfizer has drafted the terms of these agreements to be balanced andreasonable and to further the goals of both parties. Negotiating grant
agreements requires significant resources, so please ensure that yourinstitution (including your legal department) is able and willing to abideby these terms before proceeding with submission of your application
as they will need to be accepted in their entirety.

•Review and Approval
Process
Mechanism by which
Applicants will beNotified:•Grant requests received in response to a general RFP are reviewed by
Pfizer and BMS to make final grant decisions.

••

All applicants will be notified via email by the dates noted above.
Applicants may be asked for additional clarification during the review
period.

4

3Advancing Management and Care in Atrial Fibrillation and Venous Thromboembolism

Appendix A
General RFP Submission Requirements
Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins.
Note there is a 15-page limit exclusive of references. Please include the following:

Goals and Objectives••

Briefly state the overall goal of the project.
List the objectives you plan to meet with your project, in terms of learningand expected outcomes.

Needs Assessment forthe Project•

Include a description of your organization’s needs assessment for this
proposed project which may include a quantitative baseline datasummary, initial metrics, or a project starting point (please cite data on
gap analyses or relevant patient-level data that informs the statedobjectives) in your target area.

Target Audience•

Describe the primary audience(s) targeted for this project. Indicate whom
you believe will directly benefit from the project outcomes. Describe theoverall population size as well as the size of your sample population.

Project Design andMethods•

Describe the planned project, the educational approach, and the way theplanned methods address the established need.

Innovation•Explain what measures you have taken to assure that this project isoriginal and does not duplicate other projects or materials alreadydeveloped. Describe how this project builds upon existing work, pilot
projects, or ongoing projects developed either by your institution or otherinstitutions.

Evaluation andOutcomes•

In terms of the metrics used for the needs assessment, describe how
your organization will determine if the gap was addressed for the target
group. Identify the sources of data your organization anticipates using tomake the determination. Describe how your organization is expected tocollect and analyze the data. Explain the method used to control for otherfactors outside this project (e.g., use of a control group or comparison
with baseline data). Quantify the amount of change expected from thisproject in terms the target audience. Describe how your organization will
determine if the target audience was fully engaged in the project.

Dissemination Plan•

Describe how the project may have extended benefit beyond the grant.
Will the teaching materials be made available to others to use? Willthere be tools or resources that are made publicly available beyond theinitial project. Describe how the project outcomes might be broadlydisseminated.

5

3Advancing Management and Care in Atrial Fibrillation and Venous Thromboembolism

Anticipated ProjectTimeline•

Provide an anticipated timeline for your project including project start/enddates.

Additional Information•If there is any additional information you feel Pfizer should be aware ofconcerning the importance of this project, please summarize here.

Organization Detail•Describe the attributes of the institutions/organizations that will supportand facilitate the execution of the project, the leadership of the proposed
project, and the specific role of each institution in the proposed project.

Budget Narrative•Please include a budget narrative that describes in greater detail theline items specified in the budget submitted within the application•

While estimating your budget please keep the following items in mind:oo

Independent Medical Education Grants awarded by GMG
cannot be used to purchase therapeutic assets (prescription ornon-prescription).
Overhead rates of up to 28% of the total proposed projectbudget may be supported by Pfizer. Please click here fordetails.

6